Zacks Research Has Positive Estimate for Integer Q1 Earnings

Integer Holdings Co. (NYSE:ITGR) – Equities research analysts at Zacks Research increased their Q1 2026 earnings per share estimates for shares of Integer in a research note issued on Thursday, May 15th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $1.61 per share for the quarter, up from their previous forecast of $1.59. The consensus estimate for Integer’s current full-year earnings is $6.01 per share. Zacks Research also issued estimates for Integer’s Q2 2026 earnings at $1.62 EPS.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. Integer had a return on equity of 11.65% and a net margin of 6.92%. The company had revenue of $437.39 million for the quarter, compared to the consensus estimate of $428.51 million. During the same period in the previous year, the business earned $1.14 EPS. Integer’s revenue for the quarter was up 7.3% compared to the same quarter last year.

Other equities research analysts also recently issued reports about the company. KeyCorp dropped their price objective on Integer from $154.00 to $145.00 and set an “overweight” rating on the stock in a report on Monday, April 21st. Benchmark dropped their price objective on Integer from $150.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, April 25th. Truist Financial set a $150.00 price target on Integer and gave the company a “buy” rating in a report on Friday, April 25th. Oppenheimer downgraded Integer from an “outperform” rating to a “market perform” rating in a report on Friday, February 21st. Finally, StockNews.com downgraded Integer from a “hold” rating to a “sell” rating in a report on Friday, April 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $145.56.

Integer Price Performance

ITGR stock opened at $121.05 on Monday. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer has a 52-week low of $104.93 and a 52-week high of $146.36. The stock’s 50 day moving average is $118.31 and its two-hundred day moving average is $129.51. The company has a market capitalization of $4.22 billion, a PE ratio of 36.03, a P/E/G ratio of 1.72 and a beta of 1.03.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ITGR. Raymond James Financial Inc. bought a new position in Integer during the 4th quarter worth $38,073,000. Vaughan Nelson Investment Management L.P. acquired a new position in Integer during the 1st quarter worth $33,337,000. Capital Research Global Investors boosted its position in Integer by 16.0% during the 4th quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider’s stock worth $186,960,000 after acquiring an additional 194,895 shares during the period. Artisan Partners Limited Partnership acquired a new position in Integer during the 4th quarter worth $22,775,000. Finally, Nuveen LLC acquired a new position in Integer during the 1st quarter worth $17,634,000. 99.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Joseph W. Dziedzic sold 338,975 shares of the company’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $123.17, for a total transaction of $41,751,550.75. Following the completion of the transaction, the chief executive officer now directly owns 47,000 shares in the company, valued at $5,788,990. This represents a 87.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.16% of the stock is owned by company insiders.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.